An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients

Gerald P. Bodey, Linda S. Elting, John Narro, Charles Koller, Susan O'brien, Elihu Estey, Robert Benjamin

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cancer patients received cefoperazone plus sulbactam for 673 febrile episodes presumed to be caused by infection. Overall, 415 (76%) of the 545 evaluable episodes responded. There were 213 responses (84%) amongst the 254 fevers of unknown origin and 202 responses (69%) amongst the 291 documented infections. Fifty-one (61%) of the 83 episodes pneumonia and 74 (64%) of the 115 episodes of bacteraemia responded. Only 39 (58%) of the 67 infections caused by Gram-positive bacteria responded compared with 55 (86%) of 64 Gram-negative infections which included seven of eight caused by Pseudomonas aeruginosa. Eighteen (67%) of 27 polymicrobial infections responded to the regimen. Response rates were significantly lower amongst the 125 patients whose neutrophil counts decreased during therapy than amongst the 158 patients whose neutrophil counts increased. Adverse events which were possibly or probably related to antibiotic therapy were observed during 73 of the episodes; the most commonly reported side-effects were diarrhoea and skin rash. Six patients developed a coagulopathy without haemorrhage and two experienced anaphylactic reactions. In this open trial cefoperazone plus sulbactam proved to be an effective regimen for initial therapy of fever in cancer patients. It should be combined with a glycopeptide in those institutions where infections caused by methicillin-resistant staphylococci are frequently encountered.

Original languageEnglish (US)
Pages (from-to)141-152
Number of pages12
JournalJournal of Antimicrobial Chemotherapy
Volume32
Issue number1
DOIs
StatePublished - Jul 1 1993
Externally publishedYes

Fingerprint

Cefoperazone
Sulbactam
Fever
Infection
Neoplasms
Neutrophils
Fever of Unknown Origin
Therapeutics
Induced Hyperthermia
Methicillin Resistance
Glycopeptides
Gram-Positive Bacteria
Anaphylaxis
Bacteremia
Exanthema
Coinfection
Staphylococcus
Pseudomonas aeruginosa
Diarrhea
Pneumonia

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. / Bodey, Gerald P.; Elting, Linda S.; Narro, John; Koller, Charles; O'brien, Susan; Estey, Elihu; Benjamin, Robert.

In: Journal of Antimicrobial Chemotherapy, Vol. 32, No. 1, 01.07.1993, p. 141-152.

Research output: Contribution to journalArticle

Bodey, Gerald P. ; Elting, Linda S. ; Narro, John ; Koller, Charles ; O'brien, Susan ; Estey, Elihu ; Benjamin, Robert. / An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. In: Journal of Antimicrobial Chemotherapy. 1993 ; Vol. 32, No. 1. pp. 141-152.
@article{563c86b05192424796b5ccc9a4c91847,
title = "An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients",
abstract = "Cancer patients received cefoperazone plus sulbactam for 673 febrile episodes presumed to be caused by infection. Overall, 415 (76{\%}) of the 545 evaluable episodes responded. There were 213 responses (84{\%}) amongst the 254 fevers of unknown origin and 202 responses (69{\%}) amongst the 291 documented infections. Fifty-one (61{\%}) of the 83 episodes pneumonia and 74 (64{\%}) of the 115 episodes of bacteraemia responded. Only 39 (58{\%}) of the 67 infections caused by Gram-positive bacteria responded compared with 55 (86{\%}) of 64 Gram-negative infections which included seven of eight caused by Pseudomonas aeruginosa. Eighteen (67{\%}) of 27 polymicrobial infections responded to the regimen. Response rates were significantly lower amongst the 125 patients whose neutrophil counts decreased during therapy than amongst the 158 patients whose neutrophil counts increased. Adverse events which were possibly or probably related to antibiotic therapy were observed during 73 of the episodes; the most commonly reported side-effects were diarrhoea and skin rash. Six patients developed a coagulopathy without haemorrhage and two experienced anaphylactic reactions. In this open trial cefoperazone plus sulbactam proved to be an effective regimen for initial therapy of fever in cancer patients. It should be combined with a glycopeptide in those institutions where infections caused by methicillin-resistant staphylococci are frequently encountered.",
author = "Bodey, {Gerald P.} and Elting, {Linda S.} and John Narro and Charles Koller and Susan O'brien and Elihu Estey and Robert Benjamin",
year = "1993",
month = "7",
day = "1",
doi = "10.1093/jac/32.1.141",
language = "English (US)",
volume = "32",
pages = "141--152",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients

AU - Bodey, Gerald P.

AU - Elting, Linda S.

AU - Narro, John

AU - Koller, Charles

AU - O'brien, Susan

AU - Estey, Elihu

AU - Benjamin, Robert

PY - 1993/7/1

Y1 - 1993/7/1

N2 - Cancer patients received cefoperazone plus sulbactam for 673 febrile episodes presumed to be caused by infection. Overall, 415 (76%) of the 545 evaluable episodes responded. There were 213 responses (84%) amongst the 254 fevers of unknown origin and 202 responses (69%) amongst the 291 documented infections. Fifty-one (61%) of the 83 episodes pneumonia and 74 (64%) of the 115 episodes of bacteraemia responded. Only 39 (58%) of the 67 infections caused by Gram-positive bacteria responded compared with 55 (86%) of 64 Gram-negative infections which included seven of eight caused by Pseudomonas aeruginosa. Eighteen (67%) of 27 polymicrobial infections responded to the regimen. Response rates were significantly lower amongst the 125 patients whose neutrophil counts decreased during therapy than amongst the 158 patients whose neutrophil counts increased. Adverse events which were possibly or probably related to antibiotic therapy were observed during 73 of the episodes; the most commonly reported side-effects were diarrhoea and skin rash. Six patients developed a coagulopathy without haemorrhage and two experienced anaphylactic reactions. In this open trial cefoperazone plus sulbactam proved to be an effective regimen for initial therapy of fever in cancer patients. It should be combined with a glycopeptide in those institutions where infections caused by methicillin-resistant staphylococci are frequently encountered.

AB - Cancer patients received cefoperazone plus sulbactam for 673 febrile episodes presumed to be caused by infection. Overall, 415 (76%) of the 545 evaluable episodes responded. There were 213 responses (84%) amongst the 254 fevers of unknown origin and 202 responses (69%) amongst the 291 documented infections. Fifty-one (61%) of the 83 episodes pneumonia and 74 (64%) of the 115 episodes of bacteraemia responded. Only 39 (58%) of the 67 infections caused by Gram-positive bacteria responded compared with 55 (86%) of 64 Gram-negative infections which included seven of eight caused by Pseudomonas aeruginosa. Eighteen (67%) of 27 polymicrobial infections responded to the regimen. Response rates were significantly lower amongst the 125 patients whose neutrophil counts decreased during therapy than amongst the 158 patients whose neutrophil counts increased. Adverse events which were possibly or probably related to antibiotic therapy were observed during 73 of the episodes; the most commonly reported side-effects were diarrhoea and skin rash. Six patients developed a coagulopathy without haemorrhage and two experienced anaphylactic reactions. In this open trial cefoperazone plus sulbactam proved to be an effective regimen for initial therapy of fever in cancer patients. It should be combined with a glycopeptide in those institutions where infections caused by methicillin-resistant staphylococci are frequently encountered.

UR - http://www.scopus.com/inward/record.url?scp=0027239531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027239531&partnerID=8YFLogxK

U2 - 10.1093/jac/32.1.141

DO - 10.1093/jac/32.1.141

M3 - Article

VL - 32

SP - 141

EP - 152

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 1

ER -